Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells.

BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is the eighth most common cancer with the lowest overall 5-y relative survival rate. Gene expression profiling of PDAC revealed an overexpression of the macrophage migration inhibitory factor (MIF), a lymphokine involved in cell-mediated immunity and inflammation, as well as in the regulation of cellular signal transduction. MATERIALS AND METHODS Endogenous MIF expression was silenced by treatment of pancreatic cancer cell lines using two independent MIF siRNAs. The expression of MIF RNA and protein after siRNA treatment was investigated using quantitative RT-PCR and Western blot. Induction of apoptosis was analyzed using fluorescence activated cell sorting (FACS). RESULTS Transfection of MiaPaCa-2 cells with MIF siRNA resulted in a reduction of MIF RNA and protein levels by more than 85%. After treatment, we observed an inhibition of cellular proliferation accompanied by induction of apoptosis. Analysis of the phosphorylation state of Akt showed a markedly increase of the phosphorylation at the Thr308 residue. CONCLUSIONS Using post-transcriptional silencing with small interfering RNAs, we could show that MIF acts as an autocrine growth factor involved in cell cycle progression. Since MIF is a secreted protein, a therapy directed against MIF or its receptor might lead to a significant growth reduction of PDAC.

[1]  K. Sugimachi,et al.  Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  K. Iczkowski,et al.  Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer , 2005, BMC Cancer.

[3]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  D. Saur,et al.  Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. , 2007, Cancer research.

[5]  Tina Peng,et al.  Sustained Mitogen-activated Protein Kinase (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor (MIF) , 1999, The Journal of Biological Chemistry.

[6]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[7]  K. Iczkowski,et al.  Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells1 , 2006, The Journal of Immunology.

[8]  M. Crow,et al.  Macrophage migration inhibitory factor governs endothelial cell sensitivity to LPS-induced apoptosis. , 2008, American journal of respiratory cell and molecular biology.

[9]  M. Onji,et al.  Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance , 2001, European journal of clinical investigation.

[10]  H. Friess,et al.  Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling , 2008, Journal of cellular and molecular medicine.

[11]  G. Semenza,et al.  Macrophage Migration Inhibitory Factor Activates Hypoxia-Inducible Factor in a p53-Dependent Manner , 2008, PloS one.

[12]  R. Dodel,et al.  Role of MIF in Inflammation and Tumorigenesis , 2008, Oncology.

[13]  W. Weiser,et al.  Human recombinant migration inhibitory factor activates human macrophages to kill tumor cells. , 1992, Cellular immunology.

[14]  A. Marchetti,et al.  AKT1E17K in human solid tumours , 2008, Oncogene.

[15]  C. Pilarsky,et al.  Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma , 2008, British Journal of Cancer.

[16]  D. Ray,et al.  Cunning factor: macrophage migration inhibitory factor as a redox‐regulated target , 2008, Immunology and cell biology.

[17]  S. Eccles,et al.  Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.

[18]  P. Maisonneuve,et al.  Epidemiology and risk factors for pancreatic cancer. , 2006, Best practice & research. Clinical gastroenterology.

[19]  T. Calandra,et al.  Regulation of Human Lung Adenocarcinoma Cell Migration and Invasion by Macrophage Migration Inhibitory Factor* , 2007, Journal of Biological Chemistry.

[20]  T. Ohtsuka,et al.  Tumor–stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c‐Met pathway , 2006, International journal of cancer.

[21]  C. Pilarsky,et al.  Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. , 2004, Neoplasia.

[22]  M. Asaka,et al.  Pathophysiological roles of macrophage migration inhibitory factor in gastrointestinal, hepatic, and pancreatic disorders , 2005, Journal of Gastroenterology.

[23]  E. Dahl,et al.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity , 2007, Oncogene.

[24]  Bo Wang,et al.  Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. , 2008, Cancer letters.

[25]  A. Koong,et al.  Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. , 2007, Cancer research.

[26]  R. Bucala,et al.  Macrophage migration inhibitory factor: a probable link between inflammation and cancer. , 2007, Immunity.